Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market

Lumos Pharma's stock jumped Wednesday morning as a successful phase 2 trial maintained the Texan biotech’s hopes of bringing the first oral drug for pediatric growth hormone deficiency (PGHD) to market.